3.8 Review

Management and therapy for cardiomyopathy in Friedreich's ataxia

Journal

EXPERT REVIEW OF CARDIOVASCULAR THERAPY
Volume 10, Issue 6, Pages 767-777

Publisher

TAYLOR & FRANCIS INC
DOI: 10.1586/ERC.12.57

Keywords

antioxidant; cardiomyopathy; clinical measure; dorsal root ganglion; epigenetic; hypertrophic; mitochondrion

Ask authors/readers for more resources

The autosomal-recessive disorder Friedreich's ataxia is characterized by progressive ataxia, often in association with cardiomyopathy. The most frequent cause of death is cardiac dysfunction, reflecting congestive heart failure, ventricular arrhythmias and cardio-embolic stroke. With the discovery of the underlying genetic mutation, a variety of novel therapies are now progressing into clinical trials. Consequently, it is crucial to understand the features of cardiomyopathy in this disease and how new treatments may improve cardiac function. The present artcle reviews the molecular basis of the disease, the clinical features of cardiomyopathy in Friedreich's ataxia and the upcoming therapies.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

3.8
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available